Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, Nishihara, Okinawa, Japan.
Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, Nishihara, Okinawa, Japan.
Int J Oral Maxillofac Surg. 2022 Sep;51(9):1123-1130. doi: 10.1016/j.ijom.2021.12.006. Epub 2021 Dec 24.
The aim of this study was to evaluate the efficacy of intra-arterial chemoradiotherapy with docetaxel and nedaplatin for T4 maxillary sinus squamous cell carcinoma (MSSCC). Data were retrospectively analysed for 22 consecutive patients with T4 MSSCC who underwent intra-arterial chemoradiotherapy. Participants received intensity-modulated radiotherapy (70 Gy in 35 fractions) concomitantly with docetaxel (60 mg/m) and nedaplatin (80 mg/m) administered every 4 weeks for a total of three sessions. The median follow-up period was 49 months (range 12-91 months). T4a tumours were found in 16 patients (73%) and T4b tumours in six patients (27%). Cervical metastasis was found in nine patients (41%; five N2b, four N2c). The 5-year loco-regional control, disease-free survival, and overall survival rates for patients with T4a disease were 92.3%, 92.3%, and 90.3%, respectively, compared to 83.3% (P = 0.42), 66.7% (P = 0.07), and 83.3% (P = 0.46), respectively, for those with T4b disease. The 5-year loco-regional control, disease-free survival, and overall survival rates for patients with cervical lymph node metastasis were all 87.5% compared to 92.3% (P = 0.86), 84.6% (P = 0.69), and 92.3% (P = 0.93), respectively, for those without cervical metastasis. Intra-arterial chemoradiotherapy with docetaxel and nedaplatin may provide favourable loco-regional control and increased survival in T4 MSSCC.
本研究旨在评估多西他赛和奈达铂动脉内化疗联合放疗治疗 T4 上颌窦鳞状细胞癌（MSSCC）的疗效。对 22 例连续接受动脉内化疗联合放疗的 T4 MSSCC 患者进行回顾性数据分析。参与者接受强度调制放疗（70 Gy，35 次分割），同时每 4 周给予多西他赛（60mg/m2）和奈达铂（80mg/m2），共 3 个疗程。中位随访时间为 49 个月（12-91 个月）。16 例（73%）为 T4a 肿瘤，6 例（27%）为 T4b 肿瘤。9 例（41%；5 例 N2b，4 例 N2c）发现颈部转移。T4a 疾病患者的 5 年局部区域控制率、无疾病生存率和总生存率分别为 92.3%、92.3%和 90.3%，而 T4b 疾病患者分别为 83.3%（P=0.42）、66.7%（P=0.07）和 83.3%（P=0.46）。有颈部淋巴结转移的患者 5 年局部区域控制率、无疾病生存率和总生存率均为 87.5%，而无颈部淋巴结转移的患者分别为 92.3%（P=0.86）、84.6%（P=0.69）和 92.3%（P=0.93）。多西他赛和奈达铂动脉内化疗联合放疗可能为 T4 MSSCC 提供良好的局部区域控制和生存率提高。
